ACTRN12619000887178
Recruiting
Phase 4
Effects of Empagliflozin on Autonomic Nervous System Function and Cardiac Function in Patients with Type 2 Diabetes.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes
- Sponsor
- Baker Heart and Diabetes Institute
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults with established Type 2 diabetes \> 12 months on any anti\-hyperglycaemic agents except for SGLT\-2 inhibitors
- •\- HbA1c 7\.1\-10\.0%
- •\- Estimated glomerular filtration rate (e\-GFR) \> 45 ml/min
Exclusion Criteria
- •\- History of sodium glucose transporter\-2 (SGLT2\) inhibitor treatment in the past 3 months or intolerance
- •\- Age \> 75 years
- •\- Known heart failure or established cardiac disease
- •\- Treatment with beta blockers or centrally acting sympathetic blockers
- •\- Unable to perform moderate cycloergometric exercise
- •\- Chronic kidney disease stage IIIB or above (e\-GFR \<45\)
- •\- History of recurrent genital infections and Urinary Tract Infections
- •\- Hypoglycaemia requiring third party assistance in the previous 3 months
- •euglycaemic diabetic ketoacidosis in the previous 6 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Effects of empagliflozin in diabetes treatmentIRCT20191126045505N1Bojnourd University of Medical Sciences100
Completed
Phase 4
EMPYREAN StudyJPRN-jRCTs031180043Kuwahara Kouichiro113
Not yet recruiting
Phase 2
Assessment of extra-renal effects of SGLT2-inhibitors in anuric haemodialysis patients using microneurographyACTRN12623001237673Dobney Hypertension Centre20
Completed
Not Applicable
The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot studydecompensated heaat failure type 2 diabetes mellitusJPRN-UMIN000027431Department of Cardiology, National Hospital Organization Yokohama Medical Center15
Not yet recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44